EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study

Mette Søgaard, Marie Ørskov, Martin Jensen, Jamilla Goedegebuur, Eva K Kempers, Chantal Visser, Eric C T Geijteman, Denise Abbel, Simon P Mooijaart, Geert-Jan Geersing, Johanneke Portielje, Adrian Edwards und 7 weitere

Journal of Thrombosis and Haemostasis · 2025-01 · 23 (1) · 190-200

DOI: 10.1016/j.jtha.2024.09.023 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-01. Verfasst von Mette Søgaard und 18 weiteren Autor:innen. Beteiligte Einrichtung: Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg University Hospital, Gistrup, Denmark. Elect…. Hauptthemen laut MEDLINE: Neoplasms, Hemorrhage, Fibrinolytic Agents, Anticoagulants. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marie Curie, Horizon Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite uncertain benefit-risk profile near the end of life, antithrombotic therapy (ATT) is prevalent in patients with terminal cancer. OBJECTIVES: To examine adherence and persistence with ATT in terminally ill cancer patients and investigate risks of major and clinically relevant bleeding, venous thromboembolism (VTE), and arterial thromboembolism (ATE) by ATT exposure. METHODS: Using a Danish nationwide cohort of terminal cancer patients, ATT adherence in the year following terminal illness declaration was measured by the proportion of days covered (PDC) by prescription. Discontinuation was defined as a treatment gap of ≥30 days between prescription renewals. One-year cumulative incidences of bleeding complications, VTE, and ATE were calculated, considering the competing risk of death. RESULTS: During 2013-2022, 86 732 terminally ill cancer patients were identified (median age, 75 years; 47% female; median survival, 57 days). At terminal illness declaration, 37.5% were receiving ATT (66.6% platelet inhibitors, 23.0% direct oral anticoagulants, and 10.4% vitamin K antagonists [VKAs]). The mean PDC with ATT was 88% (SD, 30%), highest among platelet inhibitor users (mean PDC, 89%) and lowest among VKA users (73%). One-year ATT discontinuation incidence was 7.9% (95% CI, 7.7%-8.1%). Most patients continued ATT until death (74.8% platelet inhibitors, 58.8% direct oral anticoagulants, and 61.6% VKAs). Patients receiving ATT had a lower 1-year VTE risk but higher risks of ATE and major bleeding. CONCLUSION: Despite uncertain benefit-risk profile, most terminally ill cancer patients continue ATT until the end of life. These findings provide insights into current ATT utilization and discontinuation dynamics in the challenging context of terminal illness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHemorrhageFibrinolytic AgentsAnticoagulantsPlatelet Aggregation InhibitorsTerminal CareVenous ThromboembolismThromboembolismHumansFemaleDenmarkMaleAgedAged, 80 and overMiddle AgedRisk FactorsRisk AssessmentIncidenceTime FactorsTreatment Outcome

Stichwörter der Autor:innen

anticoagulantsdeprescriptionneoplasmspalliative careplatelet aggregation inhibitors

Substanzen

Fibrinolytic AgentsAnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg University Hospital, Gistrup, Denmark. Electronic address: mette.soegaard@rn.dk.
  • Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark; Department of Ophthalmology, Aalborg University Hospital, Gistrup, Denmark.
  • Unit for Clinical Biostatistics, Aalborg University Hospital, Gistrup, Denmark.
  • Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Hematology, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
  • Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.

Förderung

  • Marie Curie
  • Horizon Europe

Zitieren

APA

Søgaard, M., Ørskov, M., Jensen, M., Goedegebuur, J., Kempers, E. K., Visser, C., Geijteman, E. C. T., Abbel, D., Mooijaart, S. P., Geersing, G. J., Portielje, J., Edwards, A., Aldridge, S. J., Akbari, A., Højen, A. A., Klok, F. A., Noble, S., Cannegieter, S., & Ording, A. G. (2025). Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study. Journal of Thrombosis and Haemostasis, 23(1), 190-200. https://doi.org/10.1016/j.jtha.2024.09.023

Vancouver

Søgaard M, Ørskov M, Jensen M, Goedegebuur J, Kempers EK, Visser C, et al. Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study. Journal of Thrombosis and Haemostasis. 2025;23(1):190-200. doi:10.1016/j.jtha.2024.09.023

BibTeX
@article{Sgaard2025,
  author = {Søgaard, Mette and Ørskov, Marie and Jensen, Martin and Goedegebuur, Jamilla and Kempers, Eva K and Visser, Chantal and Geijteman, Eric C T and Abbel, Denise and Mooijaart, Simon P and Geersing, Geert-Jan and Portielje, Johanneke and Edwards, Adrian and Aldridge, Sarah J and Akbari, Ashley and Højen, Anette A and Klok, Frederikus A and Noble, Simon and Cannegieter, Suzanne and Ording, Anne Gulbech},
  title = {Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {1},
  pages = {190--200},
  doi = {10.1016/j.jtha.2024.09.023}
}
Kostenlos starten →